Standard regimen for methotrexate and folinic acid therapy for ectopic pregnancy
Reading Document
Medical Text Search
methotrexate ectopic pregnancy treatment regimen protocol
Medical Text Search
folinic acid leucovorin rescue methotrexate multi-dose ectopic pregnancy
GradeResponse
GradeResponse
The retrieval covers the pharmacology well. I'll now supplement with established clinical guidelines (ACOG, RCOG) and synthesize a complete answer.
Methotrexate (MTX) ± Folinic Acid for Ectopic Pregnancy
Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, preventing DNA synthesis in rapidly dividing trophoblastic tissue. Three protocols are in clinical use: single-dose, two-dose, and multi-dose (with folinic acid rescue).
Patient Selection Criteria (Medical Management Appropriate)
| Criterion | Requirement |
|---|---|
| Haemodynamic status | Stable (no signs of rupture) |
| βhCG | Generally < 5,000 IU/L (some guidelines allow up to 10,000 IU/L with close follow-up) |
| Ultrasound | No fetal cardiac activity; adnexal mass ideally < 3.5 cm |
| Free fluid | Absent or minimal |
| Renal/hepatic/haematologic function | Normal (baseline LFTs, CBC, creatinine required) |
| Commitment | Patient able and willing to attend follow-up |
(Bailey & Love's Surgery, 28th Ed., p. 1600)
Protocol 1: Single-Dose Regimen
The most widely used regimen in current practice.
| Day | Action |
|---|---|
| Day 1 | MTX 50 mg/m² IM (body surface area–based) |
| Day 4 | Measure serum βhCG |
| Day 7 | Measure serum βhCG |
Interpretation:
- ≥15% fall in βhCG from Day 4 → Day 7: success — continue weekly monitoring until undetectable.
- <15% fall: administer a second dose of MTX 50 mg/m² IM and repeat the Day 4/7 monitoring cycle.
- If two doses fail, or βhCG plateaus/rises: consider surgical management.
No folinic acid is used in the single-dose protocol.
Protocol 2: Two-Dose Regimen
A middle-ground approach with slightly higher success rates than single-dose for higher βhCG levels.
| Day | Action |
|---|---|
| Day 1 | MTX 50 mg/m² IM |
| Day 4 | MTX 50 mg/m² IM (second dose, given regardless of βhCG) |
| Day 4 & 7 | Measure βhCG |
Success criterion: ≥15% fall from Day 4 → Day 7. If not achieved, a third dose may be given or surgical management pursued.
No folinic acid is used in the two-dose protocol.
Protocol 3: Multi-Dose Regimen (with Folinic Acid/Leucovorin Rescue)
The original protocol; highest efficacy but more side effects and complexity.
| Day | Drug | Dose & Route |
|---|---|---|
| Day 1 | MTX | 1 mg/kg IM |
| Day 2 | Folinic acid (leucovorin) | 0.1 mg/kg IM |
| Day 3 | MTX | 1 mg/kg IM |
| Day 4 | Folinic acid | 0.1 mg/kg IM |
| Day 5 | MTX | 1 mg/kg IM |
| Day 6 | Folinic acid | 0.1 mg/kg IM |
| Day 7 | MTX | 1 mg/kg IM |
| Day 8 | Folinic acid | 0.1 mg/kg IM |
Monitoring: βhCG measured on MTX days (Days 1, 3, 5, 7). Stop MTX (and the subsequent folinic acid dose) once a ≥15% decline in βhCG is observed between two consecutive measurements — further doses are unnecessary.
Maximum: 4 doses of MTX (and 4 doses of folinic acid), but most patients respond after 1–3 doses.
Role of Folinic Acid (Leucovorin)
As described in Harrison's (p. 2147), MTX blocks dihydrofolate reductase and is retained intracellularly via polyglutamylation. Folinic acid (N5-formyltetrahydrofolate / leucovorin) bypasses this block, rescuing normal host cells (gut mucosa, bone marrow) from MTX toxicity without neutralising its effect on trophoblastic tissue. At the low doses used in the multi-dose ectopic protocol (0.1 mg/kg), folinic acid provides a protective effect on normal tissue; at higher oncologic doses (15 mg/m²), leucovorin is dosed to rescue marrow and mucosa from 10⁻⁸–10⁻⁶ M concentrations (Harrison's, p. 2147).
Comparative Efficacy
| Protocol | Success Rate | Advantage |
|---|---|---|
| Single-dose | ~88% | Simplest, fewest injections |
| Two-dose | ~87–92% | Better for higher βhCG |
| Multi-dose | ~93% | Highest efficacy |
Follow-Up After Any Protocol
- Weekly βhCG until undetectable (< 5 IU/L).
- Avoid: NSAIDs (increase MTX toxicity via tubular secretion competition), alcohol, folic acid supplements, prolonged sun exposure, and sexual intercourse until βhCG is undetectable.
- Avoid pregnancy for at least 3 months post-treatment.
- Repeat pelvic ultrasound if symptoms develop (pain, haemodynamic instability).
Indications to Abandon Medical Therapy
- Haemodynamic instability at any point
- Rising βhCG after two full courses of MTX
- Signs of tubal rupture (peritonism, free fluid)
- Patient non-compliance with follow-up
Dose of folinic acid
Based on the multi-dose methotrexate protocol for ectopic pregnancy:
Folinic Acid (Leucovorin) Dose
0.1 mg/kg IM, given the day after each methotrexate dose.
In Context of the Full Multi-Dose Schedule
| Day | Drug | Dose |
|---|---|---|
| Day 1 | MTX | 1 mg/kg IM |
| Day 2 | Folinic acid | 0.1 mg/kg IM |
| Day 3 | MTX | 1 mg/kg IM |
| Day 4 | Folinic acid | 0.1 mg/kg IM |
| Day 5 | MTX | 1 mg/kg IM |
| Day 6 | Folinic acid | 0.1 mg/kg IM |
| Day 7 | MTX | 1 mg/kg IM |
| Day 8 | Folinic acid | 0.1 mg/kg IM |
Key Points
- The folinic acid dose is 1/10th of the MTX dose (MTX 1 mg/kg : folinic acid 0.1 mg/kg).
- It is given 24 hours after each MTX dose, not concurrently — concurrent administration would neutralise MTX's therapeutic effect.
- MTX is stopped once βhCG falls ≥15% between two consecutive measurements; the corresponding folinic acid dose is also omitted at that point.
- Maximum of 4 folinic acid doses across the full course.
This is a shared conversation. Sign in to Orris to start your own chat.